{"id":1006,"date":"2025-03-12T09:00:00","date_gmt":"2025-03-12T09:00:00","guid":{"rendered":"https:\/\/ukpeptidesstore.co.uk\/?p=1006"},"modified":"2025-03-12T09:00:00","modified_gmt":"2025-03-12T09:00:00","slug":"retatrutide-vs-tirzepatide-vs-mounjaro","status":"publish","type":"post","link":"https:\/\/alluvipeptideshop.co.uk\/en_au\/retatrutide-vs-tirzepatide-vs-mounjaro\/","title":{"rendered":"Retatrutide vs Tirzepatide vs Mounjaro\u00ae \u2014 Which Is Best for Weight Loss? (2025)"},"content":{"rendered":"

Retatrutide vs Tirzepatide vs Mounjaro\u00ae \u2014 Full 2025 Comparison<\/h2>\n

With multiple powerful GLP-1 options available in the UK \u2014 retatrutide, tirzepatide, and brand-name Mounjaro\u00ae \u2014 choosing the right compound can be confusing. This guide provides a direct, evidence-based comparison to help you decide.<\/p>\n

The Key Difference \u2014 Mechanism of Action<\/h2>\n\n\n\n\n\n\n\n
Compound<\/th>\nMechanism<\/th>\nReceptors<\/th>\n<\/tr>\n<\/thead>\n
Retatrutide<\/td>\nTriple agonist<\/td>\nGLP-1 + GIP + GCG<\/td>\n<\/tr>\n
Tirzepatide \/ Mounjaro\u00ae<\/td>\nDual agonist<\/td>\nGLP-1 + GIP<\/td>\n<\/tr>\n
Semaglutide \/ Ozempic\u00ae<\/td>\nSingle agonist<\/td>\nGLP-1 only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The addition of glucagon (GCG) receptor activation in retatrutide is the critical difference \u2014 it adds a third fat-burning mechanism that increases resting energy expenditure, a mechanism absent from tirzepatide and semaglutide.<\/p>\n

Weight Loss Results \u2014 Head-to-Head Comparison<\/h2>\n\n\n\n\n\n\n\n
Compound<\/th>\nAverage Weight Loss<\/th>\n% Losing \u226520%<\/th>\nTrial Duration<\/th>\n<\/tr>\n<\/thead>\n
Retatrutide 24mg<\/strong><\/td>\n24.2%<\/strong><\/td>\n83%<\/strong><\/td>\n48 weeks<\/td>\n<\/tr>\n
Tirzepatide 15mg (Mounjaro\u00ae)<\/td>\n22.5%<\/td>\n56%<\/td>\n72 weeks<\/td>\n<\/tr>\n
Semaglutide 2.4mg (Ozempic\u00ae\/Wegovy\u00ae)<\/td>\n14.9%<\/td>\n32%<\/td>\n68 weeks<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Sources: Retatrutide NEJM 2023<\/a> \u00b7 Tirzepatide NEJM 2022<\/a> \u00b7 Semaglutide NEJM 2021<\/a><\/p>\n

Retatrutide vs Tirzepatide \u2014 The Practical Differences<\/h2>\n

Weight loss<\/h3>\n

Retatrutide produces meaningfully greater average weight loss (24.2% vs 22.5%). The difference becomes more pronounced at the high end \u2014 83% of retatrutide patients lost \u226520% body weight vs 56% of tirzepatide patients. For someone weighing 100kg, this is the difference between losing ~22kg vs ~24kg on average \u2014 significant in absolute terms.<\/p>\n

Side effects<\/h3>\n

Both have very similar GI side effect profiles. Retatrutide uniquely produces a modest heart rate increase (4\u20136 bpm average) due to glucagon receptor activation \u2014 this is absent with tirzepatide. For most healthy adults this is clinically insignificant, but relevant for those with cardiac concerns.<\/p>\n

Evidence base<\/h3>\n

Tirzepatide has a larger evidence base \u2014 Phase 3 SURMOUNT trials enrolled thousands of participants across multiple years. Retatrutide’s Phase 2 data is compelling but Phase 3 results are still emerging. Tirzepatide is the more established compound with more long-term safety data.<\/p>\n

Price in UK (2025)<\/h3>\n